Business, energy, technology, markets and global industry news from Business News Today

Capricor Therapeutics

PharmaDeviceNews Capricor Therapeutics
Capricor Therapeutics faces a pivotal FDA decision on deramiocel for Duchenne muscular dystrophy cardiomyopathy, with regulators weighing disputed cardiac efficacy evidence against supportive upper-limb results. Representative image.
Pharma & Biotech

Capricor lost the FDA panel vote 9-3. Why investors have not completely abandoned deramiocel

Capricor Therapeutics faces an August 22 FDA decision for deramiocel after advisers voted that the available evidence did not establish effectiveness in Duchenne muscular dystrophy cardiomyopathy. The disputed case now turns on statistical methods, the treatment indication and whether supportive upper-limb results can overcome unresolved cardiac evidence.

Read More
Representative image of clinicians reviewing cardiac and upper-limb assessments as Capricor prepares deramiocel for a decisive FDA advisory committee in Duchenne muscular dystrophy.
Pharma & Biotech

Capricor faces an FDA panel for deramiocel, but has HOPE-3 truly resolved its Duchenne evidence gap?

Capricor Therapeutics has secured a July 29 FDA advisory committee meeting for deramiocel after a positive Phase 3 trial revived the previously rejected Duchenne muscular dystrophy application. The therapy now has controlled evidence of skeletal and cardiac benefit, but regulators must still weigh endpoint interpretation, long-term external comparisons, manufacturing reliability and whether the proposed label

Read More